Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 41 % of short-term debt in 2026; threshold 65 %.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2026.
Financials
Financial year 2026
NEWPHARMA GROUP from Liège, company number BE0684465652, closed financial year 2026 with a result of € 138,686 after tax. For that financial year NEWPHARMA GROUP recorded revenue of € 60.9 million and equity of € 86.3 million. Compared with financial year 2025, the result moved from € -42,260 to € 138,686. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 21, 2026.
€ 86.3 million
▼ 1% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 138,686
▲ still € 42,260 loss in 2025
Profit after tax over the fiscal year.
€ 21,524
▲ € 20,310 vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € -493,357.
People and assets in 2026
100.9
▲ 61.7 vs 2025
Average over the fiscal year, from the social balance sheet.
€ 10.8 million
▲ 239% vs 2025
€ 107,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 17,989
▲ 10% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 12 million
▲ 8% vs 2025
€ 2.2 million is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 8.6 million
▲ € 6.5 million vs 2025
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 64 days on average.
€ 1.5 million
▲ 131% vs 2025
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Revenue | € 3,903,656 | € 8,352,719 | € 7,772,440 | € 60,938,545 | ▲ € 53.2 million |
| Profit after taxes | € -2,385,796 | € -1,236,951 | € -42,260 | € 138,686 | ▲ € 180,947 |
| Equity | € 60,982,223 | € 79,745,273 | € 86,703,012 | € 86,262,357 | ▼ 1% |
| Total debts | € 34,858,205 | € 19,233,852 | € 14,237,884 | € 22,243,267 | ▲ 56% |
| Cash | € 8,602 | € 36,661 | € 1,214 | € 21,524 | ▲ € 20,310 |
| Retained profit | € -6,517,777 | € -7,754,727 | € -42,262 | € -493,357 | ▼ € 451,095 |
| Bank debt | € 30,596,188 | € 11,332,039 | € 11,124,310 | € 11,987,976 | ▲ 8% |
| Balance sheet total | € 95,959,491 | € 99,227,746 | € 101,104,339 | € 108,599,500 | ▲ 7% |
| Employees (FTE) | 39.6 | 41.9 | 39.2 | 100.9 | ▲ 61.7 |
Key figures of NEWPHARMA GROUP, fiscal years 2022 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to NEWPHARMA GROUP?
What happened at NEWPHARMA GROUP in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- STEFAN GOETHAERT stepped down as director. NBB
- JEF COLRUYT stepped down as director. NBB
- KRIS CASTELEIN stepped down as director. NBB
- JO WILLEMYNS stepped down as director. NBB
- GJ Lifescience management SRL stepped down as director. NBB
- New annual accounts for financial year 2026: profit of € 138,686. Source: NBB ↗
- MICHAEL HAMELRIJCK became a director. NBB
- STEFAAN VANDAMME stepped down as director. NBB
In short
From € 2.4 million loss in 2022 to € 138,686 profit in 2026.
Paid € 69,797 in corporate taxes since 2022.
Best year ever: 2026, with € 138,686 profit.
Pays suppliers within 64 days on average.
A new publication or filing at NEWPHARMA GROUP? We notify you, reason included.
Follow NEWPHARMA GROUPDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind NEWPHARMA GROUP is MICHAEL HAMELRIJCK. The shares are held by Sukhino SA (100%). It owns 100% of APOTHEEK NOORDERLAAN, 100% of NEWPHARMA, 100% of MEGAPARA SAS, 100% of Apotheek Beaujean Centrum, 100% of SMARTVALUE DISTRIBUTION SRL and 100% of Z+ PHARMA itself.
Directors
According to the 2026 annual accounts
since 2026
since 2023 · until 2028
JEF COLRUYT
Director
since 2023 · until 2028
since 2023 · until 2028
since 2023 · until 2028
since 2023 · until 2026
Managing director · represented by GILLES JOURQUIN
Also active at: APOTHEEK BEAUJEAN CENTRUM, Smartvalue, NEWPHARMA
since 2021 · until 2027
Shareholders
100%
Participations
100%
100%
MEGAPARA SAS
100%
100%
Establishments
Establishment units
Physical locations of this company
Rue du Charbonnage 9
4020 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0684.465.652
- VAT number
- BE 0684.465.652
- Registered office
- Rue du Charbonnage 9, 4020 Liège
- Names & denominations
- NEWPHARMA GROUP
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 7 November 2017
- Peppol
- Active · Active since 3 Sept 2025
- Activities · NACE
Activiteiten van hoofdkantoren
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering